Last reviewed · How we verify

A Phase I Multi-Center Study to Evaluate the Safety, Tolerability, and Efficacy of Chemotherapeutic Regiments in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (COC-IDCB)

NCT02897700 Phase 1 RECRUITING

The overarching purpose of this study is to determine if the mainstay chemotherapeutic regimens represented by several genotoxic agents including but not limited to Cyclophosphamide, Doxorubicin, Epirubicin, Fluorouracil and Methotrexate (CDEFM), in the format of either a single agent or combinations are safe, tolerable, and effective in the treatment of patients with infiltrating ductal carcinoma of breast.

Details

Lead sponsorShanghai Jiao Tong University School of Medicine
PhasePhase 1
StatusRECRUITING
Enrolment300
Start date2013-01
Completion2027-12

Conditions

Interventions

Primary outcomes

Countries

China